Donor and non‐donor perspectives on receiving information from routine genomic testing of donor blood

• DOI: 10.1111/trf.17215
• Publication Date: 2022-12-07T17:56:07Z
• Authors: Rachel Thorpe; Kyle Jensen; Barbara Masser; Vera Raivola; Athina Kakkos; Kobie von Wielligh; Jonathan Wong
• Keywords: Blood collection; Blood testing; Personalized Medicine

Genomic testing is already used by blood collection agencies (BCAs) to identify rare types and ensure the best possible matching of blood. With ongoing technological developments, broader applications, such as identification genetic markers relevant donor health, will become feasible. However, perspectives donors (and potential donors) on routine genomic are under-researched.Eight online Focus Groups were conducted: four with non-donors. Participants presented three hypothetical scenarios about current future applications testing: Performing type testing; identifying associated iron metabolism; bowel cancer.Testing was perceived be an appropriate application for BCA undertake, while metabolism cancer only partially supported. raised concerns boundaries acceptable implications privacy, data security, health insurance. Perspectives non-donors all similar.The principles who benefits from role BCAs key in shaping participants' perspectives. generally agreed that should directly related donation or benefit recipient donor. Findings indicate consent communication acceptability expanded testing.